documents: FDA-2022-N-2390-0669

Regulatory documents from Regulations.gov including rules, proposed rules, notices, and supporting materials.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id agency_id docket_id title document_type subtype posted_date posted_year posted_month comment_start_date comment_end_date last_modified fr_doc_num open_for_comment withdrawn object_id
FDA-2022-N-2390-0669 FDA FDA-2022-N-2390 Vanda Pharmaceuticals, Inc.; Grant of Hearing Request Regarding a Proposal To Refuse To Approve a Supplemental New Drug Application for HETLIOZ (Tasimelteon) Notice Hearings 2026-06-03T04:00:00Z 2026 6 2026-06-03T04:00:00Z 2026-07-07T03:59:59Z 2026-06-03T17:59:58Z 2026-11046 1 0 09000064b930c153

Links from other tables